Accuracy and feasibility of initiating real-time continuous glucose monitoring in noncritically ill hospitalized patients with type 2 diabetes
World Journal of Diabetes · 2026-11-15 · 17 (11)
DOI: 10.4239/wjd.124291 ↗Abstract
BACKGROUND Continued use of personal continuous glucose monitoring (CGM) devices is recommended for people with diabetes receiving insulin therapy during hospitalization to achieve better glycemic control and reduce hypoglycemia. However, data on the initiation of real-time CGM (rt-CGM) in hospitalized patients remain limited. AIM To evaluate accuracy and feasibility of initiating Glunovo i3 rt-CGM for general-medicine inpatients with type 2 diabetes mellitus (T2DM). METHODS A total of 25 patients with T2DM were enrolled. The mean age was 72.8 ± 11.6 years, 64% were female, and the mean glycated hemoglobin was 10.0% ± 3.1%. The Glunovo i3 rt-CGM sensor and transmitter were placed on the patient’s abdomen. Medical personnel calibrated the device using capillary blood glucose (CBG) measurements. Paired CBG and sensor glucose values were analyzed to assess the accuracy of CGM using the mean absolute relative difference (MARD) and Clarke Error Grid Analysis (CEGA). RESULTS CGM was used for 7.7 ± 2.4 days, with calibration performed 2.3 ± 0.7 times/day. Among 397 paired CBG and CGM measurements, overall MARD was 12.2% ± 12.2%, with the lowest MARD observed at CBG levels > 180 mg/dL (11.0% ± 11.1%). The percentages of readings within ± 15%/15 mg/dL, ± 20%/20 mg/dL, and ± 30%/30 mg/dL were 72.8%, 82.9%, and 91.7%, respectively. Overall, 96.7% of points fell within CEGA zones A and B, with none in zone E. Time in range improved from 41.2% ± 26.2% on day 1 to 48.3% ± 22.3% during the last 72 hours (P = 0.469). CONCLUSION Initiation of the Glunovo i3 rt-CGM system in noncritically ill hospitalized patients with insulin-treated T2DM is feasible and demonstrates acceptable accuracy and safety for glucose monitoring during hospitalization.
EUVIMED